Skip to main content
Northwestern University Feinberg School of Medicine
Department of Medicine
Skip to main content

Gastroenterology and Hepatology Clinical Trials

The following searchable list includes all the Division of Gastroenterology and Hepatology, Department of Medicine clinical trials currently looking for participants. Please feel free to contact us with inquiries about any of our ongoing research.

Trials
A Multicenter Group to Study Acute Liver Failure. Long-term Outcomes of Acute Liver Failure Study Group Patients
Data Registry study for acute liver failure.
18-70 yr old adults. Acute Liver Failure (ALF) - INR > 1.5 and hepatic encephalopathy. Acute Liver Injury (ALI) - INR > 2, ALT > 10 x ULN
Ganger, Daniel RGanger, Daniel R
  • Map it 201 E. Huron St.
    Chicago, IL
NCT00518440 STU00016475
More Info

For more information on this study please contact us:

Gottstein, Jeanne H 312 694 0264
Copy
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (LEGACY)
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderatel…
A Long-Term Non-Interventional Registry to Assess Safety and Effectiveness of HUMIRA® (Adalimumab) in Patients with Moderately to Severely Active Ulcerative Colitis (LEGACY)
Hanauer, StephenHanauer, Stephen
  • Map it 201 E. Huron St.
    Chicago, IL
NCT01848561 STU00094204
More Info

For more information on this study please contact us:

Arrieta, Rose +1 312 695 5878
Copy
Healthy Control Esophageal Registry and Biorepository
This study is being done to compare how the esophagus and upper stomach work in people who have Scleroderma with symptoms of reflux disease or difficulty swallowing (dysphagia) to healthy controls. We will collect skin, esophageal and stomach biop…
This study is being done to compare how the esophagus and upper stomach work in people who have Scleroderma with symptoms of reflux disease or difficulty swallowing (dysphagia) to healthy controls. We will collect skin, esophageal and stomach biopsies (small pieces of tissue) to be used for several studies.
Must not be:
- Obese (i.e. BMI ≥30)
- Known medical illnesses that could affect esophageal function, gene expression or histology
- Have a diagnosis of an eating disorder
- Have a diagnosis of an autoimmune disease
- A current or previous smoker (smoked >100 cigarettes in lifetime)
- Have a history of alcohol abuse or addiction or score of 2 or higher on the CAGE questionnaire
- Taking antacids and/or proton pump inhibitors for heartburn
- Allergies to Fentanyl or Midolazam (sedatives used during endoscopy)
- Allergies to Lidocaine (Lidocaine anesthetic jelly used during manometry).
- Pregnant or nursing (hormones associated with pregnancy and lactation are known to affect esophageal function)
Carlson, DustinCarlson, Dustin
  • Map it 633 N. St. Clair St.
    Chicago, IL
STU00096856
More Info

For more information on this study please contact us:

Masihi, Melina +1 312 695 0330
Copy
(xIRB) An Open-Label, Multicenter Study to Evaluate Long-term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ II)
The purpose of this study is to evaluate L…
The purpose of this study is to evaluate Long-term Outcomes following treatment with ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Ganger, Daniel RGanger, Daniel R
NCT02167945 STU00102262
More Info

For more information on this study please contact us:

1-855-NU-STUDY
Copy
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Subjects with Primary Biliary Cholangitis
Primary Biliary Cirrhosis (PBC) is a serious, life--threatening, bile acid related liver disease …
Primary Biliary Cirrhosis (PBC) is a serious, life--threatening, bile acid related liver disease of unknown cause. Without treatment, it frequently progresses to liver fibrosis and eventual cirrhosis requiring liver transplantation or resulting in death. The investigational drug, Obeticholic Acid (OCA) is a modified bile acid and FXR agonist that is derived from the primary human bile acid chenodeoxycholic acid. The key mechanisms of action of OCA, including its choleretic, anti-inflammatory, and anti-fibrotic properties, underlie its hepatoprotective effects and result in attenuation of injury and improved liver function in a cholestatic liver disease such as PBC. The study will assess the effect of OCA compared to placebo, combined with stable standard care, on clinical outcomes in PBC patients.
Flamm, Steven LFlamm, Steven L
NCT02308111 STU00200837
More Info

For more information on this study please contact us:

Gottstein, Jeanne H 312 694 0264
Copy
An Open Label Extension And Safety Monitoring Study Of Moderate To Severe Ulcerative Colitis Patients Previously Enrolled In Etrolizumab Phase II/III Studies
An Open Label Extension And Safety Monitoring Study Of Moderate To Severe Ulcerative Colitis Patients Previously Enrolled In Etrolizumab Phase …
An Open Label Extension And Safety Monitoring Study Of Moderate To Severe Ulcerative Colitis Patients Previously Enrolled In Etrolizumab Phase II/III Studies
Hanauer, StephenHanauer, Stephen
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02118584 STU00200583
More Info

For more information on this study please contact us:

Arrieta, Rose +1 312 695 5878
Copy
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Etrolizumab As An Induction And Maintenance Treatment For Patients With Moderately To Severely Active Crohn’s Disease (Protocol GA29144)
A Phase III, Randomized, Double-Blind, Placebo…
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Etrolizumab As An Induction And Maintenance Treatment For Patients With Moderately To Severely Active Crohn’s Disease (Protocol GA29144)
Hanauer, StephenHanauer, Stephen
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02394028 STU00201257
More Info

For more information on this study please contact us:

Arrieta, Rose +1 312 695 5878
Copy
An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active Crohn’s Disease Previously Enrolled In The Etrolizumab Phase III Protocol GA29144 (Protocol GA29145)
An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active …
An Open-Label Extension and Safety Monitoring Study of Patients With Moderately to Severely Active Crohn’s Disease Previously Enrolled In The Etrolizumab Phase III Protocol GA29144 (Protocol GA29145)
Hanauer, StephenHanauer, Stephen
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02403323 STU00201259
More Info

For more information on this study please contact us:

Arrieta, Rose +1 312 695 5878
Copy
Phase III, Double Blind, Placebo Controlled, Multicenter Study Of The Efficacy And Safety Of Etrolizumab During Induction And Maintenance In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Refractory To Or Intolerant Of Tnf Inhibitors (Protocol GA28950)
Phase III, Double Blind, Pla…
Phase III, Double Blind, Placebo Controlled, Multicenter Study Of The Efficacy And Safety Of Etrolizumab During Induction And Maintenance In Patients With Moderate To Severe Active Ulcerative Colitis Who Are Refractory To Or Intolerant Of Tnf Inhibitors (Protocol GA28950)
Hanauer, StephenHanauer, Stephen
  • Map it 201 E. Huron St.
    Chicago, IL
NCT02100696 STU00200704
More Info

For more information on this study please contact us:

Arrieta, Rose +1 312 695 5878
Copy
Semen quality in males with inflammatory bowel disease: Influence of medication for IBD
Semen quality in males with inflammatory bowel disease: Influence of methotrexate, ustekinumab and tofacitinib treatment.
Bellaguarda, EmanuelleBellaguarda, Emanuelle
  • Map it 201 E. Huron St.
    Chicago, IL
STU00201469
More Info

For more information on this study please contact us:

Arrieta, Rose 312 695 5878
Copy
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies…
Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease
Hanauer, StephenHanauer, Stephen
NCT02914561 STU00205056
More Info

For more information on this study please contact us:

Arrieta, Rose 312 695 5878
Copy
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of …
A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn’s Disease
Hanauer, StephenHanauer, Stephen
  • Map it 259 E. Erie St. Sixteenth Floor
    Chicago, IL
NCT03077412 STU00206753
More Info

For more information on this study please contact us:

Arrieta, Rose +1 312 695 5878
Copy
Back to top